Cargando…
Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report
Metastatic thymic carcinoma is an aggressive cancer that usually responds poorly to multimodal therapies. Although surgical resection is the preferred treatment for patients with advanced or metastatic disease, the clinical prognosis is typically poor. The present study describes a 63-year-old patie...
Autores principales: | ZHAN, PING, XIE, HAIYAN, YU, LI-KE |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356389/ https://www.ncbi.nlm.nih.gov/pubmed/25789028 http://dx.doi.org/10.3892/ol.2015.2953 |
Ejemplares similares
-
Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020) -
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017) -
nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014) -
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report
por: Jiang, Jian, et al.
Publicado: (2020) -
A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
por: Patel, Shetal A., et al.
Publicado: (2021)